29,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Drug discovery is rapidly evolving with the integration of emerging technologies such as artificial intelligence (AI) and CRISPR. AI enhances the drug development process by enabling faster and more accurate analysis of biological data, optimizing lead compound identification, and predicting drug interactions. Meanwhile, CRISPR technology allows for precise gene editing, facilitating the study of genetic diseases and the development of targeted therapies.Together, these innovations are transforming traditional methods, reducing time and costs in bringing new drugs to market, and paving the way…mehr

Produktbeschreibung
Drug discovery is rapidly evolving with the integration of emerging technologies such as artificial intelligence (AI) and CRISPR. AI enhances the drug development process by enabling faster and more accurate analysis of biological data, optimizing lead compound identification, and predicting drug interactions. Meanwhile, CRISPR technology allows for precise gene editing, facilitating the study of genetic diseases and the development of targeted therapies.Together, these innovations are transforming traditional methods, reducing time and costs in bringing new drugs to market, and paving the way for personalized medicine. By leveraging big data and advanced biotechnologies, researchers can better understand disease mechanisms and develop more effective treatments, ultimately improving patient outcomes.
Autorenporträt
M.K.Vijayalakshmi is working as an Associate Professor in Department of Pharmaceutical Chemistry /Analysis at Faculty of Pharmacy, Bharath Institute of Higher Education and Research,Selaiyur. She has completed her post-graduation in Pharmaceutical Chemistry in Madras Medical College, Chennai. She has vast experience in Research and Development.